SWOG
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
- Conditions
- Stage IV Squamous Cell Lung CarcinomaRecurrent Squamous Cell Lung Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 31
- Registration Number
- NCT02785913
- Locations
- 🇺🇸
Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Conditions
- CCND1 Gene AmplificationCDK4 Gene AmplificationCCND3 Gene AmplificationStage IV Squamous Cell Lung Carcinoma AJCC v7Recurrent Squamous Cell Lung CarcinomaCCND2 Gene Amplification
- Interventions
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 53
- Registration Number
- NCT02785939
- Locations
- 🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Conditions
- Stage IV Squamous Cell Lung Carcinoma AJCC v7Recurrent Squamous Cell Lung Carcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 275
- Registration Number
- NCT02785952
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸City of Hope Antelope Valley, Lancaster, California, United States
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Conditions
- Recurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 116
- Registration Number
- NCT02766335
- Locations
- 🇺🇸
Cookeville Regional Medical Center, Cookeville, Tennessee, United States
🇺🇸Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
- Conditions
- Stage IVB Rectal CancerStage IVA Rectal CancerStage IVA Colon CancerStage IVB Colon Cancer
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 380
- Registration Number
- NCT02728804
- Locations
- 🇺🇸
Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
🇺🇸Macomb Hematology Oncology PC, Warren, Michigan, United States
🇺🇸Great Falls Clinic, Great Falls, Montana, United States
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
- Conditions
- Stage IIIA Breast CancerStage IIIA Colorectal CancerStage IIIB Colorectal CancerStage IVB Colorectal CancerStage 0 Breast CancerStage IA Non-Small Cell Lung CarcinomaStage IIIB Non-Small Cell Lung CancerStage IV Breast CancerFebrile NeutropeniaStage I Colorectal Cancer
- Interventions
- Other: Preventive InterventionOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 3665
- Registration Number
- NCT02728596
- Locations
- 🇺🇸
Saint John Macomb-Oakland Hospital, Warren, Michigan, United States
🇺🇸Dayton Physicians LLC-Atrium, Franklin, Ohio, United States
🇺🇸MultiCare Good Samaritan Hospital, Puyallup, Washington, United States
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
- Conditions
- Pancreatic AdenocarcinomaResectable Pancreatic Carcinoma
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 147
- Registration Number
- NCT02562716
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Licking Memorial Hospital, Newark, Ohio, United States
🇺🇸Geisinger Medical Group, State College, Pennsylvania, United States
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
- Conditions
- Stage IV Non-Small Cell Lung CancerRecurrent Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 174
- Registration Number
- NCT02438722
- Locations
- 🇺🇸
Onslow Memorial Hospital, Jacksonville, North Carolina, United States
🇺🇸Boston Baskin Cancer Center-Bartlett, Bartlett, Tennessee, United States
🇺🇸The Carle Foundation Hospital, Urbana, Illinois, United States
S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
- Conditions
- Constipation, Impaction, and Bowel ObstructionUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Procedure: therapeutic conventional surgeryProcedure: gastrointestinal complications management/preventionOther: quality-of-life assessment
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 221
- Registration Number
- NCT02270450
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸Long Island Jewish Medical Center, New Hyde Park, New York, United States
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 237
- Registration Number
- NCT02177695
- Locations
- 🇺🇸
Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States
🇺🇸Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States
🇺🇸Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States